These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
193 related articles for article (PubMed ID: 6792207)
1. Detoxification of urotoxic oxazaphosphorines by sulfhydryl compounds. Brock N; Pohl J; Stekar J J Cancer Res Clin Oncol; 1981; 100(3):311-20. PubMed ID: 6792207 [TBL] [Abstract][Full Text] [Related]
2. Prevention of urotoxic side effects by regional detoxification with increased selectivity of oxazaphosphorine cytostatics. Brock N; Pohl J IARC Sci Publ; 1986; (78):269-79. PubMed ID: 3108156 [TBL] [Abstract][Full Text] [Related]
3. The development of mesna for the inhibition of urotoxic side effects of cyclophosphamide, ifosfamide, and other oxazaphosphorine cytostatics. Brock N Recent Results Cancer Res; 1980; 74():270-8. PubMed ID: 6777836 [TBL] [Abstract][Full Text] [Related]
4. [Prevention of urotoxic actions of cyclophosphamide and ifosfamide by dimesna (preliminary communication) (author's transl)]. Brock N; Stekar J Arzneimittelforschung; 1982; 32(5):486-7. PubMed ID: 6809014 [TBL] [Abstract][Full Text] [Related]
5. Acrolein, the causative factor of urotoxic side-effects of cyclophosphamide, ifosfamide, trofosfamide and sufosfamide. Brock N; Stekar J; Pohl J; Niemeyer U; Scheffler G Arzneimittelforschung; 1979; 29(4):659-61. PubMed ID: 114192 [TBL] [Abstract][Full Text] [Related]
6. Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention--III. Profile of action of sodium 2-mercaptoethane sulfonate (mesna). Brock N; Pohl J; Stekar J; Scheef W Eur J Cancer Clin Oncol; 1982 Dec; 18(12):1377-87. PubMed ID: 6819957 [TBL] [Abstract][Full Text] [Related]
7. Effect of the uroprotector sodium 2-mercaptoethane sulfonate (Mesna) on the proliferation of the bladder urothelium in the rat after administration of cyclophosphamide. Kunze E; Köhnecke B; Engelhardt W; Steinröder H; Brock N; Pohl J Urol Int; 1984; 39(2):61-7. PubMed ID: 6426112 [TBL] [Abstract][Full Text] [Related]
8. The development of mesna for regional detoxification. Brock N; Pohl J Cancer Treat Rev; 1983 Sep; 10 Suppl A():33-43. PubMed ID: 6414694 [No Abstract] [Full Text] [Related]
9. [Antidote against the urotoxic effects of the oxazaphorine derivatives cyclophosphamide, ifosfamide and trofosfamide]. Brock N; Stekar J; Pohl J Naturwissenschaften; 1979 Jan; 66(1):60-1. PubMed ID: 106307 [No Abstract] [Full Text] [Related]
10. Comparison of reduced glutathione with 2-mercaptoethane sulfonate to prevent cyclophosphamide-induced urotoxicity. Cavalletti E; Tofanetti O; Zunino F Cancer Lett; 1986 Jul; 32(1):1-6. PubMed ID: 3091245 [TBL] [Abstract][Full Text] [Related]
11. Dithio-bis-mercaptoethanesulphonate (DIMESNA) does not prevent cellular damage by metabolites of ifosfamide and cyclophosphamide in LLC-PK1 cells. Mohrmann M; Ansorge S; Schönfeld B; Brandis M Pediatr Nephrol; 1994 Aug; 8(4):458-65. PubMed ID: 7524598 [TBL] [Abstract][Full Text] [Related]
12. Chloroacetaldehyde and its contribution to urotoxicity during treatment with cyclophosphamide or ifosfamide. An experimental study/short communication. Pohl J; Stekar J; Hilgard P Arzneimittelforschung; 1989 Jun; 39(6):704-5. PubMed ID: 2505783 [TBL] [Abstract][Full Text] [Related]
13. The efficacy of mesna (2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy. Andriole GL; Sandlund JT; Miser JS; Arasi V; Linehan M; Magrath IT J Clin Oncol; 1987 May; 5(5):799-803. PubMed ID: 3106585 [TBL] [Abstract][Full Text] [Related]
14. Proceedings of a symposium on ifosfamide (Mitoxana; Holoxan) and Mesna (Uromitexan). Coventry, U.K., 16-18 March 1983. Cancer Treat Rev; 1983 Sep; 10 Suppl A():1-192. PubMed ID: 6414687 [No Abstract] [Full Text] [Related]
15. Influence of mesna on urotoxic effects of selected bromosubstituted analogs of ifosfamide. Kuśnierczyk H; Konarski L; Kowalski P; Radzikowski C Arch Immunol Ther Exp (Warsz); 1997; 45(1):79-85. PubMed ID: 9090445 [TBL] [Abstract][Full Text] [Related]
16. [Prevention of urinary tract toxicity of oxazaphosphorines by a "uroprotector". Report on a field study (author's transl)]. Burkert H; Schnitker J; Fichtner E MMW Munch Med Wochenschr; 1979 Jun; 121(22):760-2. PubMed ID: 112422 [TBL] [Abstract][Full Text] [Related]
17. Urinary excretion of ifosfamide, 4-hydroxyifosfamide, 3- and 2-dechloroethylifosfamide, mesna, and dimesna in patients on fractionated intravenous ifosfamide and concomitant mesna therapy. Kurowski V; Wagner T Cancer Chemother Pharmacol; 1997; 39(5):431-9. PubMed ID: 9054957 [TBL] [Abstract][Full Text] [Related]
18. Oxazaphosphorine cytostatics: past-present-future. Seventh Cain Memorial Award lecture. Brock N Cancer Res; 1989 Jan; 49(1):1-7. PubMed ID: 2491747 [TBL] [Abstract][Full Text] [Related]
19. [Clinical evaluation of Mitexan in the prevention of urinary tract complications during treatment with Holoxan]. Czownicki Z; Utracka-Hutka B Nowotwory; 1981; 30(4):377-83. PubMed ID: 6792599 [No Abstract] [Full Text] [Related]
20. Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention. 2. Comparative study on the uroprotective efficacy of thiols and other sulfur compounds. Brock N; Pohl J; Stekar J Eur J Cancer Clin Oncol; 1981 Nov; 17(11):1155-63. PubMed ID: 7199463 [No Abstract] [Full Text] [Related] [Next] [New Search]